文章：

非小细胞肺癌肿瘤微环境特异性疗法的现状

The Current State of Tumor Microenvironment-Specific Therapies for Non-Small Cell Lung Cancer

原文发布日期：22 May 2025

DOI: 10.3390/cancers17111732

类型: Article

开放获取: 是

英文摘要：

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality. Exploration of the tumor microenvironment (TME) has resulted in dramatic advancements in the treatment of NSCLC through the advent of immunotherapy. Indeed, anti-programmed death (PD) ligand 1/PD-1 checkpoint inhibitor therapy has substantially improved survival for advanced, unresectable disease and is now being increasingly utilized in the perioperative setting for early-stage, resectable tumors. This success has generated vigorous interest in exploring other cellular players in the NSCLC TME that could be potentially targeted for therapeutic benefit. In this review, we discuss the current state of therapeutic targets in the NSCLC TME, reflect on the revolution of immunotherapy and future directions for its utilization, and reflect on how the current investigations into TME-specific targets may impact thoracic surgical care.

摘要翻译： 

非小细胞肺癌（NSCLC）仍是癌症相关死亡的主要原因。随着免疫疗法的出现，对肿瘤微环境（TME）的探索显著推动了NSCLC治疗的进展。事实上，抗程序性死亡（PD）配体1/PD-1检查点抑制剂疗法已极大改善了晚期不可切除患者的生存状况，并正日益应用于早期可切除肿瘤的围手术期治疗。这一成功激发了学界对探索NSCLC肿瘤微环境中其他潜在治疗靶点细胞的浓厚兴趣。本文综述了当前NSCLC肿瘤微环境治疗靶点的研究现状，反思了免疫疗法的变革及其未来应用方向，并探讨了当前针对肿瘤微环境特异性靶点的研究如何影响胸外科临床实践。

原文链接：

The Current State of Tumor Microenvironment-Specific Therapies for Non-Small Cell Lung Cancer